miR-101, miR-20a, and miR-17 inhibit APP expression and down regulation of these miRNAs has important therapeutic effect on the progression of AD (Zoltowska et al., 2020; Samadian et al., 2021; Liu et al., 2022). This evidence concerns the gene APP and Alzheimer disease.